Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA testing. In order to conserve the remaining reagent, a controlled process of batch testing was implemented. Therefore, you will likely see additional delays in receiving these supplemental test results.
Read about our plan to mitigate this on the Communications page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...